Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Efficacy in Major Depression
NCT03715127Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Psilocybin with Placebo (2 arms). Primary endpoints: Montgomery Asberg Depression Rating Scale at Day 32 and Beck Depression Inventory at Day 32. Started Mar 2019; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03715127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715127.